Will the EU clinical trials regulation support the innovative industry in bringing new medicines faster to patients?

Pharmaceutical Medicine

Volumn 27, Issue 2, 2013, Pages 75-82

  Atzor, Sabine ^a   Gokhale, Surendra ^a   Doherty, Michael ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Baculovirus expression group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); COOPERATION; DECISION MAKING; DRUG APPROVAL; DRUG CONTROL; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESEARCH; GOVERNMENT REGULATION; HEALTH CARE POLICY; HONESTY; HUMAN; INFORMATION DISSEMINATION; LEGAL ASPECT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 84883023917     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/s40290-013-0012-8     Document Type: Review

References (30)

1. European Commission. Europe 2020. http://ec.europa.eu/europe2020/index- en.htm. Accessed 13 Jul 2012.
2. European Parliament and the Council. Directive 2001/20/EC of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044: EN:PDF. Accessed 7 Jan 2013.
3. European Forum for Good Clinical Practice. Impact on Clinical Research of European Legislation (ICREL). Final report - second version. http://www.efgcp.be/downloads/icrel-docs/Final-report-ICREL.pdf. Accessed 12 July 2012.
4. Frewer LJ, Coles D, van der Lans IA, et al. Impact of the European clinical trials directive on prospective academic clinical trials associated with BMT. Bone Marrow Transplant. 2011;46:443-7.
5. Mason E. European Commission considers revisions to clinical trials directive. J Natl Cancer Inst. 2010;102:292-7.
6. Hoey R. The EU clinical trials directive: 3 years on. Lancet. 2007;369:1777-8.
7. European Commission. Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. http://ec.europa.eu/health/files/clinicaltrials/ 2012-07/proposal/2012-07-proposal-en.pdf. Accessed 17 July 2012.
8. European Commission. Assessment of the functioning of the "Clinical Trials Directive" 2001/20/EC. Public consultation paper. ENTR/F/2/SF D (2009) 32674. http://ec.europa.eu/health/files/clinicaltrials/docs/2009-10-09- public-consultation-paper.pdf. Accessed 16 Jul 2012.
9. Moulton B. Two years later: the impact of the EU Directive. Appl Clin Trials. 2006;1 Aug.
10. Medicines and Healthcare products Regulatory Agency (MHRA). UK response to European Commission review of the Clinical Trials Directive. http://ec.europa.eu/health/files/clinicaltrials/docs/responses-2001-20/ medicines-and-healthcare-products-regulatory-agency.pdf. Accessed 7 Jan 2013.
11. Danish Ministry of Health and Prevention. Comments on assessment of the functioning of the "Clinical Trials Directive" 2001120/EC. http://ec.europa.eu/health/files/clinicaltrials/docs/responses-2001-20/ danish-ministry-of-health-and-prevention.pdf. Accessed 7 Jan 2013.
12. Bundesinstituts für Arzneimittel und Medizinprodukte (BfArM). Statement of the Federal Institute for Drugs and Medical Devices and the Federal Institute for Vaccines and Biomedicines (Paul Ehrlich Institute) on the public consultation on the "Revision of the Clinical Trial Directive 2001/20/EC" of the European Commission. http://ec.europa.eu/health/files/ clinicaltrials/ctresp-2011-06/bfarm-pei-2.pdf. Accessed 7 Jan 2013.
13. European Patients' Forum. EPF's response to the Commission public consultation on the Clinical Trials Directive 2001/20/EC. http://ec.europa.eu/ health/files/clinicaltrials/docs/responses-2001-20/european-patient-forum.pdf. Accessed 7 Jan 2013.
14. European Commission. Roadmap. Legislative proposal on a Regulation/Directive amending the Clinical Trials Directive 2001/20/EC. http://ec.europa.eu/governance/impact/planned-ia/docs/47-sanco-clinical-trials- directive-en.pdf. Accessed 16 Jul 2012.
15. European Commission. COM (2007) 23 Communication from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of Regions. Action programme for reducing administrative burdens in the European Union. http://eur-lex.europa.eu/LexUriServ/LexUriServ. do?uri=COM:2007:0023:FIN:EN:PDF. Accessed 10 Oct 2012.
16. van Vyve D, Meunier F. Facing the challenges of the European Clinical Trials Directive - The European Organisation for Research and Treatment of Cancer Perspective. Eur Oncol. 2008;4:14-8.
17. European Federation of Pharmaceutical Industries and Associations (EFPIA). Assessment of the Functioning of the "Clinical Trials Directive" 2001/20/EC. EFPIA response to public consultation paper ENTR/F/2/SF D (2009) 32674. http://ec.europa.eu/health/files/clinicaltrials/ docs/responses-2001-20/efpia-1.pdf. Accessed 16 Jul 2012.
18. Druml C, Wolzt M, Pleiner J, et al. Research ethics committees in Europe: trials and tribulations. Intensive Care Med. 2009;35:1636-40.
19. Rice M. New data on clinical trials directive in Europe show few favorable outcomes. J Natl Cancer Inst. 2006;98:159-60.
20. European Commission. Revision of the 'Clinical Trials Directive' 2001/20/EC. Concept paper submitted for public consultation. http://ec.europa.eu/health/files/clinicaltrials/concept-paper-02-2011.pdf. Accessed 16 Jul 2012.
21. European Medicines Agency. European Commission-European Medicines Agency conference on the operation of the Clinical Trials Directive (Directive 2001/20/EC) and perspectives for the future. www.ema.europa.eu/docs/en-GB/ document-library/Report/2009/11/WC500011204.pdf. Accessed 12 July 2012.
22. European Federation of Pharmaceutical Industries and Associations (EFPIA) and European Vaccine Manufacturers (EVM). Revision of the 'Clinical Trials Directive' 2001/20/EC. EFPIA and EVM joint responses and comments in relation to concept paper submitted for public consultation. http://ec.europa.eu/health/ files/clinicaltrials/ctresp-2011-06/efpia-evm.pdf. Accessed 16 Jul 2012.
23. German Pharmaceutical Industry Assosciation (BPI). Public consultation on the assessment of the functioning of the "Clinical Trials Directive" 2001/20/EC. Public consultation paper (9th October 2009) European Commission. Comments of the German Pharmaceutical Industry Association. http://ec.europa.eu/ health/files/clinicaltrials/docs/responses-2001-20/bpi-german-pharmaceutical- industry-assosciation.pdf. Accessed 13 July 2012.
24. Gokhale S, Gasser-Stracca M. Voluntary harmonization process for multinational clinical trials in the EU. Right direction, but is it enough? Regulatory focus. http://www.raps.org/focus-online/features/features-article- view/article/1865/voluntary-harmonization-process-for-multinational-clinical- trials-in-the-eu.aspx. Accessed 16 Jul 2012.
25. European Organisation for Research and Treatment of Cancer (EORTC). Reply to public consultation revision of the "Clinical Trials Directive" 2001/20/EC concept paper. http://ec.europa.eu/health/files/clinicaltrials/ ctresp-2011-06/eortc.pdf. Accessed 7 Jan 2013.
26. European Commission. Fostering EU's attractiveness in clinical research: Commission proposes to revamp rules on trials with medicines IP/12/795. http://europa.eu/rapid/pressReleasesAction.do?reference=IP/12/795. Accessed 4 Sep 2012.
27. European Federation of Pharmaceutical Industries and Associations (EFPIA). Position on the legal proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. http://www.efpia.eu/sites/www.efpia. eu/files/efpia-key-messages-ctr-10.12.2012.pdf. Accessed 30 Jan 2013.
28. European Federation of Pharmaceutical Industries and Associations. EFPIA position on the legal proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (COM (2012) 369 final). 10 December 2012. http://www.efpia.eu/sites/www.efpia.eu/files/efpia-key-messages-ctr-10.12.2012. pdf. Accessed 10 Jan 2013.
29. European Medicines Agency. Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted in third countries and submitted in marketing authorisation applications to the EMA. EMA/712397/2009. http://www.emea.europa.eu/docs/en-GB/document-library/ Regulatory-and-procedural-guideline/2010/06/WC500091530.pdf. Accessed 7 Jan 2013.
30. US Department of Health and Human Services Food and Drug Administration. Human subjects research protections: enhancing protections for research subjects and reducing burden, delay, and ambiguity for investigators. Advance notice of proposed rulemaking. http://www.gpo.gov/fdsys/pkg/FR-2011-07-26/pdf/2011-18792. pdf. Accessed 16 Jul 2012.